MAIA Biotechnology secures a $2.3 million grant from the National Institutes of Health for its THIO-101 Phase 2 trial aimed at treating advanced non-small cell lung cancer.

Sep 24, 2025•6 days ago

Amount Raised

$2.3 Million

ChicagoHealth CareBiotechnology

Investors

National Institutes Of Health

Description

MAIA Biotechnology has been awarded a $2.3 million grant by the NIH for the THIO-101 Phase 2 clinical trial. This funding will mainly support patient enrollment costs in the U.S. for adults resistant to previous treatment. The grant funds will be allocated over three years from 2025 to 2027

Company Information

Company

MAIA Biotechnology

Location

Chicago, Illinois, United States

About

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns